Friedreich's ataxia (FA) is a rare inherited genetic disorder. The disease typically manifests either in childhood or in early adolescence...
Frataxin Deficiency Meeting Its Match: New Discovery can cure Friedreich’s ataxia
Friedreich’s ataxia (FA) is a rare inherited genetic disorder. The disease typically manifests either in childhood or in early adolescence, frequently between the ages of 5 and 15. Many affected people only live into their 30s or 40s. Researchers have not yet developed a widely accepted treatment that can slow down or change the disease itself at the moment, and not everyone responds well to the treatments that are available.
New genetic information on Friedreich’s ataxia, a rare inherited genetic disorder, has emerged. Scientists, using the roundworm C. elegans, reported a genetic modification that allows cells to live without frataxin, a crucial mitochondrial protein that is absent in patients suffering from the disease. The findings demonstrated that specific mutations in FDX2 and NFS1 enable cells to overcome the lack of frataxin by regaining the capacity to form iron sulfur clusters. These clusters support numerous metabolic processes and are essential for generating cellular energy.
Additionally, the scientists found that while lowering FDX2, either by mutation or by deleting one copy of the gene, helps restore cluster creation and enhances cell health. On the other hand, high levels of FDX2 obstruct this process.
Meisel, J. D., Joshi, P. R., Spelbring, A. N. Hong W., Sandra M. W., Presli P. W., Maria M., Jason G. M., David P. B., Gary R., Vamsi K. M., carried out the study and published it in Nature (2025) under the title “Mutations in mitochondrial ferredoxin FDX2 suppress frataxin deficiency” in December 2025.
EENTECH STEM Magazine has included this research in its list of the Top 10 Biology Discoveries of 2025.
Potential benefits for curing Friedreich’s ataxia
This research expands our knowledge of the causes of Friedreich’s ataxia and, if researchers verify the findings in humans, may result in improved treatments by identifying a novel drug target.
Improve the quality of life for those with Friedreich’s ataxia
The discovery of a genetic modifier that allows cells to survive without frataxin, the key protein lacking in this disease, could lead researchers to develop new treatments that could help manage or slow the progression of symptoms. This could significantly improve the daily lives of those affected by this debilitating disorder.
Advance understanding of mitochondrial diseases
Friedreich’s ataxia is a mitochondrial disorder, and the insights gained from this research may translate to better understanding and treatment approaches for other mitochondrial diseases, which can have widespread impacts on health and function.
Potential for drug target discovery
If the findings from the C. elegans model are confirmed in humans, the genetic modifier identified could serve as a new drug target, potentially leading to the development of therapies that address the root cause of Friedreich’s ataxia.
Informing future research directions
This work deepens the scientific understanding of the molecular basis of Friedreich’s ataxia and can also guide future research efforts. It can, therefore, be aimed at finding a cure or more effective management strategies for this rare but devastating disorder.
Educational and career opportunities
The potential career opportunities for students with respect to this finding could be:
Neurodegenerative disease research
- Studying the underlying genetic as well as molecular mechanisms of Friedreich’s ataxia and other neurodegenerative disorders
- Developing animal models and cell-based systems to further investigate disease pathways
- Exploring novel therapeutic approaches, including targeting the identified genetic modifier
Mitochondrial biology and bioenergetics
- Investigating the role of mitochondria and mitochondrial dysfunction in Friedreich’s ataxia and also other mitochondrial disorders.
- Exploring the regulation as well as the maintenance of mitochondrial function.
- Developing treatments that address mitochondrial-related pathologies.
Translational research and drug development
- Bridging the gap between basic science discoveries and clinical applications
- Validating findings from model organisms in human studies
- Designing and testing new drug candidates targeting the identified genetic modifier or other relevant pathways
Reference
Meisel, J.D., Joshi, P.R., Spelbring, A.N. et al. Mutations in mitochondrial ferredoxin FDX2 suppress frataxin deficiency. Nature (2025). https://doi.org/10.1038/s41586-025-09821-2
Additionally, to stay updated with the latest developments in STEM research, visit ENTECH Online. Basically, this is our digital magazine for science, technology, engineering, and mathematics. Also, at ENTECH Online, you’ll find a wealth of information.
- Author
- Latest Posts
I have completed my Master’s in Zoology and am a passionate, curiosity-driven science enthusiast aiming to transform complex scientific ideas in a manner that are easy to understand hence, educate, and inspire.
My journey began with an inherent fascination for understanding how life works at the molecular, cellular, and systemic levels. Over time, this curiosity expanded into a desire to share that understanding with others through clear, engaging communication.
I have an experience of working on the projects in the field of Entomology which has provided me hands-on experience with various research techniques. Besides, I have also gained experience of lab work as well as developed communication skills during the course of my bachelors and masters.
With a strong foundation in life sciences and a growing interest in Medical and Biological research, I have cultivated a writing style that merges scientific facts with creativity.
My experience in teaching has also taught me has also taught me to develop an understanding of what are the interests of people and how to communicate them effectively.
I am also committed to lifelong learning, actively engaging in Interdisciplinary learning, so as to broaden my perspective.
